Oxadiazole Compounds for Refractory Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current epilepsy therapeutic agents have limitations in efficacy, with a significant proportion of patients experiencing refractory seizures despite treatment with established drugs like levetiracetam.
Innovation Solution
Development of a novel compound represented by Chemical Formula 1, or its optical isomers, stereoisomers, or pharmaceutically acceptable salts, which are used to create a pharmaceutical composition for the prevention or treatment of epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing epilepsy therapeutic agents (levetiracetam, topiramate, lamotrigine) are used, then treatment coverage is achieved, but efficacy for refractory patients is insufficient (30-40% of patients remain untreated)
Solution Approach 1:
The patent modifies the chemical structure of existing epilepsy medications by introducing oxadiazole rings and various substituents (halo, alkyl, alkoxy, carbamoyl groups) at different positions. This structural parameter change creates a series of novel compounds with potentially improved pharmacological properties and broader applicability to refractory epilepsy cases.
Solution Approach 2:
The patent combines the oxadiazole core structure with various functional groups and substituents to create composite molecular structures. These composite compounds integrate multiple pharmacophores that may work synergistically to enhance anticonvulsant activity and broaden the range of epilepsy types treated.
2Reliability
If novel compounds with improved efficacy are developed, then treatment effectiveness increases, but drug development complexity and time increase
Solution Approach 1:
The patent systematically divides the molecular structure into a core oxadiazole unit and various substitutable positions (R1-R6 groups). This segmentation allows independent optimization of different molecular regions, enabling methodical development and testing of multiple derivatives without completely redesigning the entire molecule each time.
Solution Approach 2:
The oxadiazole core structure serves as a universal scaffold that can accommodate multiple different substituent groups while maintaining the fundamental anticonvulsant mechanism. This multi-functionality allows a single core structure to generate multiple candidate drugs with potentially different profiles for various epilepsy types.
Data Source
AI summary
Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.